Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Crisis And Violence In Mumbai: Experiences From A Centre For Vulnerable Women And Children
In this week"s open access journal PLoS Medicine, Nayreen Daruwalla and
generic viagra online
Cyclist Tackles Amazing Feat To Raise Money For The American Lung Association
It"s not every day one wakes up and decides to ride their bike from San Francisco to Washington, D.C., but if you are Shawne Camp, anything is possible. Camp suffers from an extremely painful and rare lung disease called spontaneous pneumothorax, which can cause a sudden collapse of the lung. After enduring chest tubes, surgery to essentially glue his right lung to his chest wall and countless hours of pulmonary rehabilitation, Shawne has since made a full recovery. Drugshop to buy zoloft online and other pills.
News of the day
Meckel's Diverticulum Masked By Intermittent Recurrent Subocclusive Episodes
Meckel"s diverticulum (MD) is the most frequent congenital abnormality of the small bowel and it is often difficult to diagnose. It is usually asymptomatic but approximately 4% are symptomatic with complications such as bleeding, intestinal obstruction, and inflammation. Daniela Codrich et al presents a case of Meckel"s diverticulum masked by a long period of intermittent recurrent subocclusive episodes. Their findings were published on June 14, 2009 in the World Journal of Gastroenterology.
Medical Devices

Bosentan Is Cost-Effective For Patients With Moderate PAH

Bosentan appears to be a more cost-effective initial treatment option for patients with moderate pulmonary arterial hypertension (PAH), classified as WHO functional class III, than no active intervention. A cost-utility model was constructed to evaluate the cost-effectiveness of bosentan compared with no active intervention, both added to palliative care in the UK. In the model, simulated patients remained on their initial intervention until death or until they deteriorated to functional class IV, which triggered initiation of intravenous epoprostenol treatment. In the base-case analysis, which assumed that first line treatment did not affect survival, bosentan was more effective and less costly than no active intervention. When survival benefits associated with bosentan treatment were taken into consideration, bosentan was found to be a potential cost effective first line treatment. The work, led by Matt Stevenson was conducted at the University of Sheffield. Dr Stevenson commented: "Long-term follow-up data from randomised controlled trials show that bosentan significantly delays progression to more severe states compared with no active intervention. This results in both potential cost-savings due to a reduction in the duration of relatively expensive epoprostenol treatment and in an improvement in the quality of life for patients." This study is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research and help health care leaders to make decisions that are solidly evidence-based. The journal is published bi-monthly and has a regular readership of over 4,000 clinicians, decision-makers, and researchers worldwide. ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care res wisely, fairly, and efficiently. ISPOR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009